Windlas Biotech Ltd

Stage 3 · Topping · week 2

As of 20 Nov 2026, Windlas Biotech is in Stage 3, the topping phase, now in week 2 (since 11 Nov 2026). It closed at ₹961, 16.8% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. More about the company

₹961.3
Close, 20 Nov 2026
-2.16% on the day
₹1,984 Cr · Small cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dPharmaceuticals 42.4%-13.9 pts

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

RS rank

Edge

—

WINDLAS's uptrend is tiring: 2 weeks into a top. A topping stock either breaks back out or rolls over into a decline, and the next few weeks usually settle which.

Its relative strength is 77 of 99, above the middle among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.

Is WINDLAS early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S2 74w
S2 17w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 74w → S3 11w → S4 2w → S1 2w → S2 6w → S3 1w → S4 7w → S1 4w → S2 5w → S3 4w → S4 13w → S1 3w → S4 7w → S1 11w → S2 17w → S3 1w current
Total tracked: 169 weeks across 16 stage runs.

WINDLAS among Pharmaceuticals51st of 118 by relative strength

All 118 →
Stocks in Pharmaceuticals ranked by relative strength, with stage and one-month change
#StockStageRS1M
1BLISSGVSStage 2 · wk 4999+4.6%
2KPLStage 2 · wk 4499+20.5%
3FREDUNStage 2 · wk 3398+24.0%
4VENUSREMStage 3 · wk 1098−1.5%
5RUBICONStage 3 · wk 498+18.7%
6SAKARStage 2 · wk 5598+13.1%
7BAFNAPHStage 2 · wk 2398+1.9%
8INDSWFTLABStage 2 · wk 2398−7.4%
…51WINDLASStage 3 · wk 277+9.1%
vs 52W High
-16.8%
₹705.8 lo₹1,154.8 hi
16.8% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 2
1w13w26w
Week 2, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
9.2%
200 DMA: ₹880.3 · rising
The stock still holds above its 200-day average, but the trend has flattened. A close below the line would add to the Stage 4 risk.
Rel Volume
0.29x
vs 50-day avg
Volume was well below average. Quiet sessions say little in a topping stock. Volume on the down days matters more.
Trend Health
↑ ⇈
Short-term trend rising strongly, and accelerating
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+9.1%
3M
-0.4%
6M
+20.4%
YTD
+20.9%
1Y
+15.7%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
Sector has 58 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
42.4%
20d Δ
-13.9pp
1M return
+8.3%
3M return
+2.1%
Industry Stage-2 % · last 20 days
Industry has 48 Stage 2 leaders. See Pharmaceuticals Stage 2 →

Mutual fund holdings

Held by 3 mutual funds in portfolios to October 2026: 2 active funds and 1 index funds and ETFs.

In October, among active funds: 1 increased.

1 increased or opened0 reduced or exited
Largest active holders, by weight in the fund
All 3 funds and what each did in October

Mutual funds holding WINDLAS: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
Not in any scan now.
Last appeared 7 Oct 2026
Last appeared 27 Aug 2026
Last appeared 14 Jul 2026
12 appearances in the last 60 days.
Recent Stage Timeline
2026-11-20S3
Wk 2 · Vol 0.29x
2026-11-19S3
Wk 2 · Vol 0.24x
2026-11-18S3
Wk 2 · Vol 0.25x
2026-11-17S3
Wk 1 · Vol 0.18x
2026-11-16S3
Wk 1 · Vol 0.23x
2026-11-13S3
Wk 1 · Vol 0.45x
2026-11-12S3
Wk 1 · Vol 0.24x
2026-11-11S32→3
Wk 1 · Vol 0.38x
2026-11-09S2
Wk 17 · Vol 0.33x
2026-11-06S2
Wk 17 · Vol 15.00x
2026-11-05S2
Wk 16 · Vol 1.52x
2026-11-04S2
Wk 16 · Vol 0.33x
Moving averages & range
50 DMA
₹999.4
200 DMA
₹880.3
52W High
₹1,154.8
52W Low
₹705.8
5D Low
₹961.3
Resistance levels (recent highs)
20d High
₹1,013.2
60d High
₹1,154.8
120d High
₹1,154.8
250d High
₹1,154.8
Next resistance
+5.4%
to 20d High
P/E (TTM)
32.0
Forward —
Earnings Growth (YoY)
+1.9%
Revenue +20.4%
ROE
+12.1%
Profit margin +6.7%
Dividend Yield
0.63%
P/B 3.6

Windlas Biotech: quick answers

What stage is Windlas Biotech in?

As of 20 Nov 2026, Windlas Biotech (WINDLAS) is in Stage 3, the topping phase. It entered Stage 3 on 11 Nov 2026 and is in week 2. What the four stages mean

Is Windlas Biotech in an uptrend?

Its uptrend has stalled. Windlas Biotech is in Stage 3, the topping phase that follows an advance. It trades 9.2% above its 200-day average, which is rising.

How far is Windlas Biotech from its 52-week high?

Windlas Biotech closed at ₹961 on 20 Nov 2026, 16.8% below its 52-week high of ₹1,155. Its 52-week low is ₹706.

How has Windlas Biotech performed over the past year?

As of 20 Nov 2026, Windlas Biotech is up 15.7% over the past year and up 20.9% so far in 2026.

Which sector and industry is Windlas Biotech in?

Windlas Biotech is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals

About this companyHealth Care· Pharmaceuticals

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.